Dorsey, I am hopeful!
Around 6/04, DNAP informed Dutton Associates that they expected Statinome to go into clinical trials late 04 or early 05. I have not seen anything that would suggest that these trials have started. I expect that with some information from the FDA on these types of tests the product could be out within 2 years….. IMHO…..I would love to see Statinome out first over Ovanome. I bel. the current worldwide number one drug is lipitor. This does not directly mean that Statinome would be a cash windfall but I do think that there is a bigger market for Statinome over Ovanome...again this IMHO. The only thing that makes me balk a bit concerning if and when Statinome would/will come out is the last quarterly 10QSB/A. I could not find any mention of Statinome. They mentioned Ovanome several times but not Statinome. However, in the annual report the following was stated about Statinome:
The primary objective of our near term research and development efforts in pharmacogenomics will be to expand our library of predictive drug response tests to include multiple therapeutic areas including commonly used FDA approved drug
therapies. We currently have two pharmacogenomic tests in development, Ovanome TM and Statinome TM . In addition, it is our goal to continue to expand, improve and broaden our current products, ANCESTRYbyDNA TM and DNAWitness TM through
research and development. Although our products are diverse and address different market areas and needs, the base technology is the same.
And…
STATINS AND ACE INHIBITORS
We are developing a test, Statinome(TM), for the cardiac drug market. Statins are drugs used to treat patients at increased risk of heart disease. Approximately 50% of the U.S. population is at risk of heart disease as a result of high cholesterol and related hormonal and other chemical imbalances. While Statins have demonstrated effectiveness at cholesterol reduction, reportedly decreasing incidence of heart disease by 10.3% from 1990 to 1994, adverse
reactions from statins can include liver damage, kidney failure and a form of advanced muscular degeneration. Approximately 2-5% of patients must discontinue
statin use due to these adverse side effects. If accepted for commercial use, we believe Statinome TM will reduce substantially, the risks associated with adverse response.
Our current study includes two adverse side effects associated with statins, liver and adverse muscular response. These two side effects comprise most of the side effects associated with statins. We have identified numerous markers
associated with these potentially life-threatening responses. We have performed initial research in conjunction with a group of physicians to study and classify….
Big Blue
